Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.38 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180224 | 0.93 | CYP17A1 (0.47) | CYP17A1CYP11B1CYP11B2IDO1TDO2 | |
| SCHEMBL5569838 | 0.90 | CYP17A1 (0.41) | CYP17A1CYP11B1CYP11B2TRPC3TRPC6 | |
| SCHEMBL5569827 | 0.88 | CYP17A1 (0.45) | CYP17A1CYP11B1CYP11B2DPP4 | |
| SCHEMBL5573342 | 0.86 | CYP17A1 (0.45) | CYP17A1CYP11B2KDM1A | |
| SCHEMBL1180560 | 0.84 | CYP17A1 (0.36) | CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL1196282 | 0.81 | CYP17A1 (0.50) | CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL1768139 | 0.80 | CYP11B1 (0.45) | CYP11B1CYP11B2IDO1TDO2 | |
| SCHEMBL5133449 | 0.79 | CYP19A1 (0.48) | CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL5571001 | 0.79 | CYP19A1 (0.48) | CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL5048062 | 0.79 | CYP19A1 (0.48) | CYP17A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680079-B2 | Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-03-25 | — | — | US | disclosed |
| US-20070225232-A1 | Tetrahydro-Imidazo [1,5-A] Pyridyin Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225232-A1 | Tetrahydro-Imidazo [1,5-A] Pyridyin Derivatives as Aldosterone Synthase Inhibitors | CYP21A2, CYP11B1, REN | CYP17A1 5/4885CYP11B1 2/4885CYP11B2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.